Generics, Pipeline Wins, and a Pivotal Earnings Report
Novo Nordisk enters a pivotal week with Canada approving first Ozempic generics, oral Ozempic exceeding prescription expectations, and…
Oral Ozempic Arrives as Q1 Results Loom
Novo Nordisk launches oral Ozempic in US pharmacies, faces Q1 earnings test amid margin concerns, and prepares obesity…
Q1 Earnings Loom as Valuation Debate Intensifies
Novo Nordisk faces pivotal Q1 earnings amid a 36% YTD stock drop, competitive pressure from Eli Lilly, and…
Generic Competition Meets a Pipeline Showcase
Novo Nordisk enters a critical period with Q1 earnings due May 6, a Canadian Ozempic generic launch, stock…
Generics, Q1 Results, and a Pipeline Showcase
Novo Nordisk enters a critical period with Q1 earnings, a Canadian Ozempic generic launch, and obesity conference data,…
Generics, Price Wars, and a Steep Valuation Gap
Novo Nordisk faces a turbulent period with a 20% stock drop, Eli Lilly’s US market dominance, and Canada’s…
Novo Nordisk Caught Between FDA Tailwind and a Brutal Revenue Outlook
FDA proposal to curb cheap copycats boosts Novo Nordisk shares 4.8%, but pricing pressure, competition, and a grim…
Novo Nordisk’s Pipeline Progress Collides With a Darkening Revenue Outlook
Novo Nordisk balances rare-disease wins and obesity pipeline data against a grim 2026 revenue forecast and rising competition…
Canadian Generic Launch and Q1 Results Loom
Health Canada authorizes Dr. Reddy’s biosimilar semaglutide, threatening Novo Nordisk’s Ozempic revenue as share buyback reaches 3.44 billion…
Novo Nordisk Juggles Pipeline Advances and Generic Threat as Share Buyback Hits $3.44 Billion
Novo Nordisk launches Phase 3 knee OA trial, gains FDA fast-track for heart drug, as first Ozempic generic…
Novo Nordisk Juggles Pipeline Wins and Core Business Headwinds
Novo Nordisk advances rare heart disease drug Coramitug with FDA Fast Track, reports positive oral semaglutide data in…
Novo Nordisk to present new data on Wegovy®, women with obesity and next-generation weight loss treatments at European Congress on Obesity
Analyses of the higher dose of Wegovy® (semaglutide 7.2 mg) and Wegovy® pill (oral semaglutide 25 mg) show…